Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma

Ryu,Yoon‑Jong; Choe,Ji‑Young; Lee,Kyoungyul; Ahn,Soon‑Hyun

doi:10.3892/ol.2019.11087

Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma

Authors:
- Yoon‑Jong Ryu
- Ji‑Young Choe
- Kyoungyul Lee
- Soon‑Hyun Ahn
View Affiliations

Affiliations: Department of Otorhinolaryngology, Kangwon National University School of Medicine, Chuncheon, Gangwon 24341, Republic of Korea, Department of Pathology, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi 14068, Republic of Korea, Department of Pathology, Kangwon National University Hospital, Chuncheon, Gangwon 24289, Republic of Korea, Department of Otorhinolaryngology, Head and Neck Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea
Published online on: November 13, 2019 https://doi.org/10.3892/ol.2019.11087
Pages: 343-349
Copyright: © Ryu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The recent development of the cancer stem cell (CSC) model has been heralded as a new era in thyroid cancer research. The aim of this study was to evaluate the presence of CD44+ and CD24‑ tumor cells in papillary thyroid carcinoma (PTC) as markers of aggressiveness and poor prognosis. Patients with PTC, who underwent successful surgical resections between January 2003 and December 2012 at a single tertiary hospital, were included in this study. Tissue arrays were prepared from 454 primary tumor tissues. Immunohistochemistry (IHC) was performed to detect the CSC markers CD24 and CD44 on the tissue arrays. IHC was graded using a semi‑quantitative histology scoring system based on the extent and intensity of staining. Subsequently, the association between IHC results and clinicopathological characteristics and recurrence‑free survival (RFS) was analyzed. In 454 patients, 39 cases recurred during the 70‑month median follow‑up period, with some patients exhibiting multiple sites of relapse. The results of a Kaplan‑Meier survival analysis and univariate log‑rank test demonstrated that sex (P=0.008), age (P=0.002), cN1b, defined as metastasis to unilateral, bilateral, or contralateral neck lymph nodes or retropharyngeal lymph nodes (P<0.001), pN1, defined as pathologically proven lymph node metastasis >5 (P<0.001), tumor size >2 cm (P<0.001), extrathyroidal extension (P=0.001) and CD24‑ (P<0.001) were prognostic factors for RFS. CSC marker combinations (CD44+/CD24‑) also exhibited statistical significance in the log‑rank test. In conclusion, expression of the CSC markers CD44+ and CD24‑ in PTC tissue samples was associated with RFS. The combination of CD44+ and CD24‑ exhibited a statistically significant negative association with RFS and a strong association with gross extra‑thyroidal extension.

View Figures

View References

1	Ito Y, Nikiforov YE, Schlumberger M and Vigneri R: Increasing incidence of thyroid cancer: Controversies explored. Nat Rev Endocrinol. 9:178–184. 2013. View Article : Google Scholar : PubMed/NCBI
2	National_Cancer_Information_Center, . Korea cancer registry statistics 2014National Cancer Information Center; Goyang: 2016
3	Cho BY, Choi HS, Park YJ, Lim JA, Ahn HY, Lee EK, Kim KW, Yi KH, Chung JK, Youn YK, et al: Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid. 23:797–804. 2013. View Article : Google Scholar : PubMed/NCBI
4	Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al: 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
5	Moharil RB, Dive A, Khandekar S and Bodhade A: Cancer stem cells: An insight. J Oral Maxillofac Pathol. 21:4632017. View Article : Google Scholar : PubMed/NCBI
6	Ahn SH, Henderson YC, Williams MD, Lai SY and Clayman GL: Detection of thyroid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab. 99:536–544. 2014. View Article : Google Scholar : PubMed/NCBI
7	Fedchenko N and Reifenrath J: Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue-a review. Diagn Pathol. 9:2212014. View Article : Google Scholar : PubMed/NCBI
8	Perrier ND, Brierley JD and Tuttle RM: Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 68:55–63. 2018. View Article : Google Scholar : PubMed/NCBI
9	Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP and Parmentier C: Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 55:794–804. 1985. View Article : Google Scholar : PubMed/NCBI
10	Coburn M, Teates D and Wanebo HJ: Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131). Ann Surg. 219:587–595. 1994. View Article : Google Scholar : PubMed/NCBI
11	Kim WG, Kim EY, Yim JH, Han JM, Jeon MJ, Kim TY, Ryu JS, Gong G, Hong SJ, Kim WB and Shong YK: Comparison of different staging systems for predicting recurrence of papillary thyroid carcinoma. Endocrinol Metab. 26:53–61. 2011. View Article : Google Scholar
12	Hwangbo Y, Kim JM, Park YJ, Lee EK, Lee YJ, Park DJ, Choi YS, Lee KD, Sohn SY, Kim SW, et al: Long-term recurrence of small papillary thyroid cancer and its risk factors in a Korean multicenter study. J Clin Endocrinol Metab. 102:625–633. 2017.PubMed/NCBI
13	Nagayama Y, Shimamura M and Mitsutake N: Cancer stem cells in the thyroid. Front Endocrinol (Lausanne). 7:202016. View Article : Google Scholar : PubMed/NCBI
14	Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, et al: In vitro identification and characterization of CD133(pos) cancer Stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One. 3:e35442008. View Article : Google Scholar : PubMed/NCBI
15	Friedman S, Lu M, Schultz A, Thomas D and Lin RY: CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One. 4:e53952009. View Article : Google Scholar : PubMed/NCBI
16	Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B and Nestor M: Evaluation of cancer stem cell markers CD133, CD44, CD24: Association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One. 9:e946212014. View Article : Google Scholar : PubMed/NCBI
17	Tuttle RM, Haugen B and Perrier ND: Updated American Joint Committee on Cancer/Tumor-Node-Metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth edition): What changed and why? Thyroid. 27:751–756. 2017. View Article : Google Scholar : PubMed/NCBI
18	Bi Y, Meng Y, Wu H, Cui Q, Luo Y and Xue X: Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis. J Surg Oncol. 113:144–151. 2016. View Article : Google Scholar : PubMed/NCBI
19	Horimoto Y, Arakawa A, Sasahara N, Tanabe M, Sai S, Himuro T and Saito M: Combination of cancer stem cell markers CD44 and CD24 is superior to ALDH1 as a prognostic indicator in breast cancer patients with distant metastases. PLoS One. 11:e01652532016. View Article : Google Scholar : PubMed/NCBI
20	Eramo A, Haas TL and De Maria R: Lung cancer stem cells: Tools and targets to fight lung cancer. Oncogene. 29:4625–4635. 2010. View Article : Google Scholar : PubMed/NCBI
21	Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI